PE20060317A1 - XANTINE DERIVATIVES AS SELECTIVE AGONISTS OF THE NICOTINIC ACID RECEPTOR - Google Patents

XANTINE DERIVATIVES AS SELECTIVE AGONISTS OF THE NICOTINIC ACID RECEPTOR

Info

Publication number
PE20060317A1
PE20060317A1 PE2005000170A PE2005000170A PE20060317A1 PE 20060317 A1 PE20060317 A1 PE 20060317A1 PE 2005000170 A PE2005000170 A PE 2005000170A PE 2005000170 A PE2005000170 A PE 2005000170A PE 20060317 A1 PE20060317 A1 PE 20060317A1
Authority
PE
Peru
Prior art keywords
nicotinic acid
acid receptor
selective agonists
alkyl
diona
Prior art date
Application number
PE2005000170A
Other languages
Spanish (es)
Inventor
Ivan Leo Pinto
Shahzad Sharooq Rahman
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060317A1 publication Critical patent/PE20060317A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 H, ALQUILO C1-C4 SUSTITUIDO O NO POR CN, CF3; R2 ES ALQUILO C3-C10, ALQUILO C1-C10 SUSTITUIDO CON 1 O MAS GRUPOS DE F, CN, ENTRE OTROS; R3 ES HALOGENO, CN. SON COMPUESTOS PREFERIDOS: 8-CLORO-3-(4-PENTEN-1-IL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; (8-CLORO-2,6-DIOXO-1,2,6,7-TETRAHIDRO-3H-PRIN-3-IL)ACETONITRILO; 8-CLORO-3-(4,4,4-TRIFLUOROBUTIL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR DE ACIDO NICOTINICO HM74A UTILES EN ENFERMEDADES DEL METABOLISMO DE LIPIDOS, INSUFICIENCIA CARDIACA, ARTERIOSCLEROSIS, TROMBOSIS, ANGINA, ENTRE OTROSREFERS TO A COMPOUND OF FORMULA I, WHERE R1 H, C1-C4 ALKYL SUBSTITUTE OR NOT BY CN, CF3; R2 IS C3-C10 ALKYL, C1-C10 ALKYL SUBSTITUTED WITH 1 OR MORE GROUPS OF F, CN, AMONG OTHERS; R3 IS HALOGEN, CN. PREFERRED COMPOUNDS ARE: 8-CHLORINE-3- (4-PENTEN-1-IL) -3,7-DIHYDRO-1H-PURINE-2,6-DIONA; (8-CHLORO-2,6-DIOXO-1,2,6,7-TETRAHYDRO-3H-PRIN-3-IL) ACETONITRILE; 8-CHLORO-3- (4,4,4-TRIFLUOROBUTIL) -3,7-DIHYDRO-1H-PURINE-2,6-DIONA; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE SELECTIVE AGONISTS OF THE HM74A NICOTINIC ACID RECEPTOR USEFUL IN DISEASES OF LIPID METABOLISM, HEART FAILURE, ARTERIOSCLEROSIS, THROMBOSIS, ANGINA, AMONG OTHERS

PE2005000170A 2004-02-14 2005-02-11 XANTINE DERIVATIVES AS SELECTIVE AGONISTS OF THE NICOTINIC ACID RECEPTOR PE20060317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds

Publications (1)

Publication Number Publication Date
PE20060317A1 true PE20060317A1 (en) 2006-06-22

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000170A PE20060317A1 (en) 2004-02-14 2005-02-11 XANTINE DERIVATIVES AS SELECTIVE AGONISTS OF THE NICOTINIC ACID RECEPTOR

Country Status (26)

Country Link
US (5) US7713982B2 (en)
EP (1) EP1781657B1 (en)
JP (2) JP5001012B2 (en)
KR (1) KR101100601B1 (en)
CN (2) CN101863888B (en)
AR (1) AR047669A1 (en)
AU (1) AU2005212816C1 (en)
BR (1) BRPI0507604A (en)
CA (1) CA2556073C (en)
CY (1) CY1114022T1 (en)
DK (1) DK1781657T3 (en)
ES (1) ES2406732T3 (en)
HK (1) HK1104530A1 (en)
HR (1) HRP20130406T1 (en)
IL (1) IL177051A (en)
MA (1) MA28357A1 (en)
MY (1) MY148937A (en)
NO (1) NO337281B1 (en)
NZ (1) NZ548496A (en)
PE (1) PE20060317A1 (en)
PL (1) PL1781657T3 (en)
PT (1) PT1781657E (en)
SG (1) SG157242A1 (en)
SI (1) SI1781657T1 (en)
TW (1) TWI350289B (en)
WO (1) WO2005077950A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004796A (en) * 1999-11-12 2007-01-30 Biogen Inc Polycycloalkylpurines as adenosine receptor antagonists.
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CA2556073C (en) * 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
CN102558075A (en) 2004-12-03 2012-07-11 先灵公司 Substituted piperazines as CB1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
JP4975739B2 (en) 2005-05-17 2012-07-11 シェーリング コーポレイション Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1896396A1 (en) 2005-06-14 2008-03-12 F.Hoffmann-La Roche Ag Anthranilic acid derivatives
JP5113046B2 (en) 2005-06-28 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション Niacin receptor agonists, compositions containing such compounds and methods of treatment
KR20080034993A (en) * 2005-08-10 2008-04-22 스미스클라인 비참 코포레이션 Xanthine derivatives as selective hm74a agonists
AR059056A1 (en) * 2006-01-20 2008-03-12 Schering Corp HETEROCICLOS COMPO AGONISTAS OF THE NICOTINIC ACID RECEPTOR FOR THE TREATMENT OF DYSLIPIDEMIA
BRPI0711879A2 (en) 2006-05-23 2012-01-10 Hoffmann La Roche compounds, process for their manufacture, method for treating and / or preventing diseases that are modulated by hm74a agonists and uses of the compounds
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
DE602007010312D1 (en) 2006-06-23 2010-12-16 Incyte Corp PURINONE DERIVATIVES AS HM74A AGONISTS
US7511050B2 (en) 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
EP2139895A1 (en) 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (en) * 2011-05-04 2013-01-09 北京工业大学 Method for preparing N7-guanine alkylate
CN103360394B (en) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-chlorotheophylline preparation method
JP6678685B2 (en) * 2015-01-30 2020-04-08 上海珊▲頓▼医▲薬▼科技有限公司Ｓｈａｎｔｏｎ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Prevention or treatment of uric or gouty diseases
CN104892610B (en) * 2015-05-27 2016-08-24 福建师范大学 A kind of preparation method of 8-ester group caffeine derivative
CN105622610A (en) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 Method for preparing xanthine compound
CN109661238B (en) 2016-07-27 2023-07-25 哈里斯制药公司 Therapeutic combinations for the treatment of erythrocyte disorders
CN106632061B (en) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 Synthesis method of 1- (4-phenyl-1-alkyl-1H-imidazole-2-yl) ethanone and derivative thereof
WO2018130443A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP4034101A1 (en) * 2019-09-25 2022-08-03 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN112724141A (en) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 GPR109A protein receptor inhibitor and preparation and application thereof
CN113262882B (en) * 2021-07-21 2021-09-17 北京矿冶研究总院 Cation collector, preparation method and application in phosphorite reverse flotation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
ATE230990T1 (en) 1992-03-04 2003-02-15 Cell Therapeutics Inc ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6780865B1 (en) * 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
ATE236160T1 (en) * 1999-08-31 2003-04-15 Univ Vanderbilt SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (en) * 2000-07-28 2003-01-24 Inside Technologies PORTABLE ELECTRONIC DEVICE COMPRISING SEVERAL INTEGRATED NON-CONTACT CIRCUITS
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP2004512278A (en) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム Statins (HMG-CoA reductase inhibitors) as novel immunomodulators, immunoinhibitors and anti-inflammatory agents
SI1757606T1 (en) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Xanthinderivatives for use as medical agents and the preparation thereof
EP1377834A2 (en) * 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
CA2556073C (en) 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
KR20080034993A (en) 2005-08-10 2008-04-22 스미스클라인 비참 코포레이션 Xanthine derivatives as selective hm74a agonists
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
AU2005212816C1 (en) 2010-03-04
CN101103030B (en) 2010-10-13
PL1781657T3 (en) 2013-08-30
AR047669A1 (en) 2006-02-01
TW200536537A (en) 2005-11-16
US20100160354A1 (en) 2010-06-24
US20150080418A1 (en) 2015-03-19
IL177051A (en) 2013-01-31
JP5020848B2 (en) 2012-09-05
MY148937A (en) 2013-06-14
ES2406732T3 (en) 2013-06-07
CN101863888A (en) 2010-10-20
US20130150383A1 (en) 2013-06-13
IL177051A0 (en) 2006-12-10
AU2005212816B2 (en) 2009-07-23
NO20064151L (en) 2006-11-06
SG157242A1 (en) 2009-12-29
WO2005077950A3 (en) 2007-04-19
CA2556073C (en) 2012-01-10
CN101863888B (en) 2012-07-18
MA28357A1 (en) 2006-12-01
US20100010021A1 (en) 2010-01-14
BRPI0507604A (en) 2007-07-03
EP1781657B1 (en) 2013-03-27
WO2005077950A2 (en) 2005-08-25
HK1104530A1 (en) 2008-01-18
HRP20130406T1 (en) 2013-06-30
AU2005212816A1 (en) 2005-08-25
US8394808B2 (en) 2013-03-12
CY1114022T1 (en) 2016-07-27
TWI350289B (en) 2011-10-11
JP5001012B2 (en) 2012-08-15
PT1781657E (en) 2013-05-23
KR20060126772A (en) 2006-12-08
CN101103030A (en) 2008-01-09
US8268839B2 (en) 2012-09-18
JP2008120831A (en) 2008-05-29
JP2007522176A (en) 2007-08-09
CA2556073A1 (en) 2005-08-25
EP1781657A2 (en) 2007-05-09
NZ548496A (en) 2010-02-26
KR101100601B1 (en) 2011-12-29
US7713982B2 (en) 2010-05-11
DK1781657T3 (en) 2013-06-10
NO337281B1 (en) 2016-02-29
US20070135456A1 (en) 2007-06-14
SI1781657T1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
PE20060317A1 (en) XANTINE DERIVATIVES AS SELECTIVE AGONISTS OF THE NICOTINIC ACID RECEPTOR
PE20060949A1 (en) FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
PE20061442A1 (en) HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA
AR038419A1 (en) DERIVATIVES OF PIRIDINE AND QUINOLINE
PE20140630A1 (en) BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE
CY1111757T1 (en) XANTHINI PRODUCTS AS ELECTRIC SUSPENSIONS HM74A
PE20130402A1 (en) SUBSTITUTE 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
PE20081800A1 (en) NEW DERIVATIVES OF 3 - ([1,2,4] TRIAZOLO [4,3-a] PYRIDIN-7-IL) BENZAMIDE
PE20030940A1 (en) PYRIDINE AND PYRIMIDINE DERIVATIVES
PE20060298A1 (en) BENZHIMIDAZOLONE CARBOXYL ACID DERIVATIVES
Glennon et al. The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs
MXPA05011710A (en) Fused pyrimidine derivatives with crf activity.
UY27965A1 (en) HETEROCYCLIC DERIVATIVES
PE20081806A1 (en) IMIDAZO- AND SUBSTITUTE TRIAZOLOPYRIMIDINES
ATE427926T1 (en) CYCLOALKYLAMIN DERIVATIVES
CY1106375T1 (en) USE OF EPIGASTINE IN THE TREATMENT OF ALLEPIC RHINITIS/EPENDIFUCIITIS
EA200802203A1 (en) DIQUETOPYPERSON AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
ECSP045368A (en) "ANTAGONISTS OF THROMBINE RECEPTORS"
AR052314A1 (en) TIENOPIRIDINONE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS
AR023971A1 (en) DERIVATIVES OF 4,5,6,7-TETRAHYDROINDAZOL, PROCEDURE FOR THE PREPARATION OF THEMSELVES AND THEIR USE AS ANTITUMOR AGENTS
AR004320A1 (en) NEW BICYCLE CONDENSED PIRIMIDINE COMPOUNDS; A PROCEDURE FOR ITS PREPARATION; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS, IN PARTICULAR AS INHIBITORS OF THE TYROSINE KINASE.
PE20210856A1 (en) SUBSTITUTE DERIVATIVES OF CARBOXAMIDE DIHYDROPIRAZOLO PIRAZINE
CL2014001309A1 (en) Compounds derived from [1,2,3] triazolo [4,5-d] -pyrimidine, cannabinoid receptor agonists 2; obtaining process; pharmaceutical composition; use for the treatment or prophylaxis of pain, atherosclerosis, diabetic retinopathy, diabetes, liver fibrosis, heart failure, among others.
PE20060585A1 (en) DERIVATIVES OF 2-AMIDO-4-PHENYLTIAZOLE AS ANTAGONISTS OF CHEMOKINES AND THEIR PREPARATION
AR052772A1 (en) CRYSTAL FORMS AND PROCESS TO PREPARE ESPIRO-HYDANTOINE COMPOUNDS

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed